For information about COVID-19, including symptoms and prevention, please read our COVID-19 patient guide. Please also consider supporting Weill Cornell Medicine’s efforts against the pandemic.

Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma.

TitleFinal report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma.
Publication TypeJournal Article
Year of Publication2020
AuthorsBreen WG, S Anderson K, Carrero XW, Brown PD, Ballman KV, O'Neill BP, Curran WJ, Abrams RA, Laack NN, Levitt R, Galanis E, Buckner JC, Shaw EG
JournalNeuro Oncol
Date Published2020 Jan 30
ISSN1523-5866
Abstract

BACKGROUND: The optimal radiation dose for adult supratentorial low grade glioma is unknown. The aim of this study was to provide a final update on oncologic and cognitive outcomes of high dose versus low dose radiation for low-grade glioma.

METHODS: Between 1986 and 1994, 203 patients with supratentorial low grade glioma were randomized (1:1) to 50.4 Gy in 28 fractions versus 64.8 Gy in 36 fractions after any degree of resection.

RESULTS: For all patients, median OS was 8.4 years (95% CI: 7.2 - 10.8). Median progression-free survival (PFS) was 5.2 years (95% CI: 4.3 - 6.6). Median follow-up is 17.2 years for the 33 patients still alive.

CONCLUSIONS: Long-term follow-up indicates no benefit to high-dose over low-dose radiation for low-grade gliomas. Cognitive function appeared to be stable after radiation as measured by MMSE.

DOI10.1093/neuonc/noaa021
Alternate JournalNeuro-oncology
PubMed ID32002556
Division: 
Biostatistics
Category: 
Faculty Publication